China
Africa
Explore chapters and articles related to this topic
Integration with the Interdisciplinary Care Team
Published in Amy J. Litterini, Christopher M. Wilson, Physical Activity and Rehabilitation in Life-threatening Illness, 2021
Christopher M. Wilson, Amy J. Litterini
Acupuncture: According to a systematic review by Garcia et al.43 acupuncture is an appropriate intervention for chemotherapy-induced nausea and vomiting. A meta-analysis by Tao et al.44 found acupuncture to result in small-to-large effects on improving pain, fatigue, sleep disturbance, and gastrointestinal distress. Specific to cancer survivors referred for PC (n = 68), Miller et al.45 found statistically significant reductions in the symptoms of pain, anxiety, depression, drowsiness, dyspnea, fatigue, nausea, and well-being after the first, and across all subsequent acupuncture treatments (P <0.001).
Overview of changes in cancer treatment strategies
Published in Susan F. Dent, Practical Cardio-Oncology, 2019
Grace Tang, Christine Brezden-Masley
5-HT3 receptor antagonists (5-HT3 RAs) or serotonin blockers are typically used to control chemotherapy-induced nausea and vomiting (102). While clinical studies are limited, QTc prolongation has been identified in 5-HT3 RAs such as ondansetron and dolasetron and arrhythmias from granisetron (102,103). Elderly patients (>70 years old) are at greater risk due to polypharmacy and use of cardiotoxic therapeutics (103).
Nausea and Vomiting in Cancer Patients
Published in John Kucharczyk, David J. Stewart, Alan D. Miller, Nausea and Vomiting: Recent Research and Clinical Advances, 2017
While a great deal of variability exists from one patient to another and from one drug to another, chemotherapy-induced nausea and vomiting generally comes on after a latency period of at least 1 h, persists for a few hours to a few days after the chemotherapy, and is followed by anorexia that gradually resolves over several days.1,56,57 Occasionally the nausea and vomiting can be protracted, lasting for 2 weeks or more.1
Efficacy of ondansetron against emesis induced by a multiple-day cisplatin-based chemotherapy regimen for malignant lymphoma
Published in Hematology, 2021
Takahiro Kamiya, Masatoshi Sakurai, Taku Kikuchi, Mikio Okayama, Kota Mizuno, Tomohiko Tanigawa, Yuya Koda, Jun Kato, Takehiko Mori
It is important to maintain treatment intensity and maximize efficacy while minimizing distress in cancer patients undergoing chemotherapy. Chemotherapy-induced nausea and vomiting (CINV) is the most common adverse effect, and proper management of CINV is essential [1–3]. Cisplatin has been widely used for a variety of cancer chemotherapies. In the guidelines for CINV, cisplatin is classified as a high-emetic-risk antineoplastic agent, and several agents – i.e. NK1 receptor antagonist (NK1RA), dexamethasone and 5-hydroxytryptamine-3 receptor antagonist (5-HT3RA) – are recommended for use with cisplatin [4–6]. Although the guidelines separately assess and classify the emetic risk of each anticancer agent, the emetic risk for regimens that combine multiple anticancer agents has not been fully evaluated. The ESHAP regimen consists of multi-day cisplatin (25 mg/m2/day for 4 days) along with etoposide, methylprednisolone and cytarabine, and is the salvage chemotherapy regimen commonly used for refractory or relapsed lymphoid malignancies [7,8]. The ESHAP regimen contains a high-dose of the steroid methylprednisolone (500 mg/day), which often induces antiemetic effects [9,10], and the guidelines do not specify whether NK1RA is needed as an additional antiemetic.
The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy
Published in Expert Opinion on Drug Safety, 2019
The control of chemotherapy-induced nausea and vomiting (CINV) has improved significantly with the development of a number of new classes of agents; the 5- hydroxytryptamine-3 (5-HT3) receptor antagonists [1–3], the neurokinin-1 (NK-1) receptor antagonists [3–6], the corticosteroid dexamethasone [1–3], and olanzapine, an antipsychotic which blocks multiple neurotransmitters in the central nervous system [7–9]. These agents have significantly improved the control of emesis when used in various combinations for patients receiving either moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). The control of chemotherapy-induced nausea remains a significant clinical issue [1,10], although the recent use of olanzapine has shown efficacy in nausea control [7]. If CINV is not well controlled, patients’ quality of life may be significantly affected with patients returning to an outpatient facility or the emergency department on the days post-chemotherapy for hydration and/or emesis or nausea control. Poor control of CINV also has the potential for compromised treatment adherence [1,3,6].
Randomized Study of the Effect of Dietary Counseling During Adjuvant Chemotherapy on Chemotherapy Induced Nausea and Vomiting, and Quality of Life in Patients With Breast Cancer
Published in Nutrition and Cancer, 2019
Safa Najafi, Shahpar Haghighat, Mahsa Raji Lahiji, Elham RazmPoosh, Maryam Chamari, Reyhaneh Abdollahi, Marziyeh Asgari, Mitra Zarrati
Meanwhile, chemotherapy induced nausea and vomiting (CINV) might be associated with serious complications such as weakness, weight loss, electrolyte imbalance, esophageal rupture, dehydration, or anorexia (5). Further, CINV has found to have significant negative effects on QoL of patients undergoing chemotherapy, which could be a major barrier to the effective chemotherapy treatment (6,7). Indeed, patients with dehydration, disability, malnutrition, electrolyte imbalance, or those who have undergone surgery or radiotherapy might be more exposed to the serious complications of CINV (6,8). Moreover, other risk factors may increase the likelihood of CINV such as individuals under the age of 50 yr, female gender as well as a history of alcohol consumption, vomiting following a previous chemotherapy, motion sickness, vomiting, and nausea during pregnancy and anxiety (7,9).